Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Allogene Therapeutics
St. Jude Children's Research Hospital
UNC Lineberger Comprehensive Cancer Center
Fate Therapeutics
UNC Lineberger Comprehensive Cancer Center
University of Arizona
Case Comprehensive Cancer Center
Dana-Farber Cancer Institute
University Health Network, Toronto
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
Stanford University
Caribou Biosciences, Inc.
Fate Therapeutics
Fate Therapeutics
Chinese PLA General Hospital
Bristol-Myers Squibb
Fate Therapeutics
The Affiliated People's Hospital of Ningbo University
Weill Medical College of Cornell University
Loyola University
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Icahn School of Medicine at Mount Sinai
M.D. Anderson Cancer Center
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
University of Maryland, Baltimore
University of Pittsburgh
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Alliance for Clinical Trials in Oncology
Seagen Inc.
Massachusetts General Hospital
Dana-Farber Cancer Institute
University of Kentucky
RenJi Hospital
Emory University
Children's Oncology Group
National Cancer Institute (NCI)
Northwestern University
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins